Form 4: Relay Therapeutics Director Receives Stock Option Grant

Director Mark Murcko was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Mark Murcko received a grant of 32,947 stock options for Relay Therapeutics, Inc. (RLAY) common stock.
• The options have an exercise price of $14.09 per share.
• The grant date for these options is June 9, 2026.
• The options are scheduled to expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance or strategic direction.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $14.09 exercise price.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, aligning governance with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The vesting schedule (one year or next annual meeting) is consistent with standard corporate governance practices for board members in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Relay Therapeutics, RLAY, Form 4, Insider Trading, Stock Options, Director Compensation